Trusted Partner

The Difference is in the Data

MMS is the data-focused CRO driving pharmaceutical and biotech innovation with unparalleled regulatory expertise and technological innovation. Our experts across four continents are available to support your programs 24 hours a day with an industry-leading Sponsor satisfaction rating.

Full Service Biometrics

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

Regulatory Submissions

From the Investigational New Drug (IND) application stage through New Drug Applications (NDA), our deep expertise ensures that your drug development process is efficient, compliant, and strategically aligned with standards set by global health authorities.

Safety & Risk Management

Comprehensive pharmacovigilance, safety and risk management from Phase 1 through post approval, tailored to your specific needs.

Therapeutic Expertise

From industry-firsts to well-researched indications, MMS brings specialized knowledge in rare diseases, psychedelics, oncology and radiopharmaceuticals, central nervous system (CNS) disorders, and many others.

Functional Service Provider (FSP)

A flexible and scalable FSP model, providing the right level of oversight, scale, and governance to achieve your long- and short-term strategic goals.

What Differentiates MMS From Other CROs?

Responsive

MMS is more responsive, taking responsibility for the success of every project with consistent staff and proactive solutions that exceed the expectations of a CRO partner.

Adaptable

MMS is more adaptable, knowing your satisfaction and top outcomes are dependent on our ability to remain nimble and make smart decisions based on scientifically-sound data.

Focused

MMS is more focused, providing data-centric solutions and innovative technology and processes that help accelerate and de-risk the development and approval of your therapy.

Sponsor feedback
This team never stopped working towards our deadline, and from day one, we were impressed with the efficient and smart decisions brought forth by MMS to bring this drug to market.
SVP, Global Regulatory Affairs
Sponsor feedback
The choice in collaborating with MMS to meet this milestone… was simple, given their deep scientific knowledge and strategic resource models.
Dr. Steven Gullans, CEO
Sponsor feedback
I cannot thank the MMS Team for the outstanding support you’re providing to ensure these are prepared for submission. I am continuously impressed with the MMS team and truly value the partnership.
Global Pharma Sponsor

AI and Technology

Sponsors can rest assured knowing that MMS will bring new levels of innovation and technology to our processes and deliverables.

2006
MMS Founded
in Michigan
950
Loyal
Colleagues
Globally
50
Marketing
Applications in the
Last 5 Years
1
CRO you can
trust

MMS Insights

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization

perspectives

July 16th, 2024

Key Steps to Successful CMC Authoring of IND and IMPD Submissions

webinar

July 11th, 2024

The Rising Burden of Pharmacovigilance (PV) Requirements in Early Drug Development

perspectives

July 9th, 2024

Managing RTOR Submissions: How to Run a Successful Race from the Top Line Starting Line

perspectives

July 2nd, 2024

Part 1: RWD Noninterventional Study Design and FDA Engagement Opportunity for Early Stage Oncology

webinar

June 26th, 2024

A Psychedelic Shift: Assessing the Potential for Nonmedical Use in a Changing Regulatory Landscape

perspectives

June 21st, 2024

Peer-Reviewed Journal Articles: The Crucial Role of Publication in the Pharmaceutical Industry

perspectives

June 14th, 2024

A Structured Approach to Benefit-Risk Assessment Throughout Product Development in the Pharmaceutical Industry

perspectives

June 6th, 2024

Datacise and Diversity in Patient Enrollment: Combining Geospatial and Demographic Data to Aid Site Selection

perspectives

May 29th, 2024

Confined Deferrals in Clinical Trial Applications: Anticipating the Revised EU CTR Transparency Rules

perspectives

May 21st, 2024

Psychedelics and Regulatory Considerations Part II: A Shift in Lexicon and Implications of “Nonmedical Use” On Labelling